Q32 Bio (QTTB) to Announce Quarterly Earnings on Wednesday

Posted by George Bondi on Aug 3rd, 2026

Q32 Bio (NASDAQ:QTTB – Get Free Report) is expected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $1.00 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Q32 Bio (NASDAQ:QTTB – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14. On average, analysts expect Q32 Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Q32 Bio Stock Performance

NASDAQ:QTTB opened at $15.68 on Monday. Q32 Bio has a twelve month low of $1.57 and a twelve month high of $23.57. The company has a current ratio of 5.36, a quick ratio of 5.36 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $13.29 and a two-hundred day moving average price of $8.08. The company has a market capitalization of $265.87 million, a P/E ratio of 5.89 and a beta of 0.24.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Cantor Fitzgerald initiated coverage on shares of Q32 Bio in a research report on Monday, May 18th. They set an “overweight” rating for the company. Weiss Ratings upgraded Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Mizuho assumed coverage on shares of Q32 Bio in a report on Friday, May 22nd. They set an “outperform” rating and a $14.00 price objective for the company. Oppenheimer lifted their price objective on shares of Q32 Bio from $20.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, HC Wainwright increased their price target on Q32 Bio from $13.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $30.00.

Get Our Latest Report on Q32 Bio

Insider Activity at Q32 Bio

In related news, Director Diyong Xu bought 1,875,000 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $15,000,000.00. Following the completion of the acquisition, the director directly owned 3,502,987 shares in the company, valued at approximately $28,023,896. This represents a 115.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc bought 1,875,000 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were purchased at an average cost of $8.00 per share, with a total value of $15,000,000.00. Following the transaction, the director owned 3,502,987 shares in the company, valued at approximately $28,023,896. The trade was a 115.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 34.46% of the company’s stock.

Institutional Investors Weigh In On Q32 Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Opaleye Management Inc. bought a new position in shares of Q32 Bio in the 4th quarter valued at $708,000. Renaissance Technologies LLC boosted its position in Q32 Bio by 110.6% during the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock worth $331,000 after buying an additional 52,300 shares during the period. Jane Street Group LLC bought a new position in Q32 Bio during the 2nd quarter worth $69,000. AQR Capital Management LLC bought a new position in shares of Q32 Bio during the first quarter worth about $68,000. Finally, Two Sigma Investments LP acquired a new position in shares of Q32 Bio in the 3rd quarter worth approximately $62,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Company Profile

(Get Free Report)

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.